Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical GuideReportar como inadecuado




Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advances in Therapy

, Volume 34, Issue 3, pp 620–637

First Online: 13 February 2017Received: 24 December 2016DOI: 10.1007-s12325-017-0488-9

Cite this article as: De Caterina, R., Ageno, W., Boriani, G. et al. Adv Ther 2017 34: 620. doi:10.1007-s12325-017-0488-9

Abstract

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke-systemic embolism in atrial fibrillation AF and in the treatment of venous thromboembolism VTE, after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

KeywordsAtrial fibrillation Edoxaban Non-vitamin K antagonist oral anticoagulants Oral anticoagulants Venous thromboembolism Vitamin K antagonists Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-0987F0607ED0B3A4.

Download fulltext PDF



Autor: Raffaele De Caterina - Walter Ageno - Giuseppe Boriani - Paolo Colonna - Angelo Ghirarduzzi - Giuseppe Patti - Roberta Ross

Fuente: https://link.springer.com/







Documentos relacionados